DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20201345

Outcomes of multi drug resistant tuberculosis under programmatic conditions: the experience

Gayatri Devi Yellapu, Preethi Koyyana, Vasundhara Nammi, Priyanka Dharshini Dondapati, Priyanka Boppe

Abstract


Background: Tuberculosis is the most common cause of death from an infectious disease worldwide after HIV/AIDS. Drug resistant tuberculosis continues to be a public health crisis. India stands, one among 27 “high burden” MDR countries and has over 2 million new TB cases every year and TB kill’s nearly 1000 people every day. The WHO 2018 Global Tuberculosis Report estimated that, worldwide, approximately 3.5 percent of all new TB cases and 18 percent of previously treated cases are caused by MDR or rifampicin-mono resistant strains.

Methods: Presumptive drug resistance TB cases were subjected for CBNAAT or LPA to detect resistance patterns. About 231 cases of MDR/RR TB cases after pre-treatment evaluation started on CAT- IV regimen and both interim and final outcomes were analyzed.

Results: Out of 231cases 172(74.4%) were males and 59(25.6%) were females with age between 13-75yrs. Total of 194 cases culture conversion occurred out of which 28 cases the cultures were reverted back to positives. Final Outcomes were, cured in 84 (36.3%) cases, treatment completed in 42 (18.18%) cases, defaulters in 31 (13.4%) cases, turned to be XDR in 10 (4.32%) cases, treatment failure in 10 (4.32%) cases, 50 (21.6%) cases died, 3(1.29%) cases were transferred out.

Conclusions: Approximately 2/3rd of MDR/RR TB cases are retreatment sputum positive cases. Successful outcome observed in 54.54% of cases only. High rates of deaths and defaulters alarm the necessity of more effective implementation and surveillance of the programme.


Keywords


Multi drug resistant tuberculosis, Outcomes, Pulmonary tuberculosis, Resistance patterns standardized regimen

Full Text:

PDF

References


World Health Organization, Global Tuberculosis Report 2018. Available at: http://www.who.int/tb/publications/global_report/en/. Accessed 01 October 2018.

World Health Organization, iris institutional repository for information sharing: Tuberculosis control in the South- East Asia Region ;annual report 2015. Available at: https://apps.who.int/iris/handle/10665/154550.

Accessed 11 November 2018.

World Health Organization, Multidrug and Extensively Drug‑resistant TB (M/XDR‑TB) 2010 Global Report on Surveillance and Response. WHO Global Report; 2010. Available at: http://www.apps.who.int/iris/bitstream/10665/44286/1/9789241599191_eng.pdf. Accessed 05 October 2018.

Ministry of health & family welfare: central tuberculosis division: government of India. India tb report 2018. Available at: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=4160&lid=2807. Accessed December 2016.

Lange C, Abubakar I, Alffenaar JWC, Bothamley G, Caminero JA, Carvalho ACC et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014 Jul;44(1): 23-63.

Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-Plus for Patients with Multidrug-resistant Tuberculosis in India: Early Results After Three Years. Ind J Chest Diseases and Allied Sci. 2007;49:75-80.

Dhingra VK, Rajpal S, Mittal A, Hanif M . Outcome of multidrug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc. 2008 jan;55(1):15-21.

Monitoring and outcome definitions. In: Guidelines on programmatic management of drug resistant tuberculosis in India 2017. Chapter 8:88-90.

Drobniewski F, Eltringham I, Graham C, Magee JG, Smith EG, Watt B. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax. 2002 Sep 1;57(9):810-6.

Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing ‘DOTS plus. Br Med J. 1998;317:671-4.

Patel SV, Nimavat KB, Alpesh PB, Shukla LK, Shringarpurea KS, Mehta KG, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (mdrtb) in western India: A prospective study. J Infection and Public Health. 2016;9:478-84.

Dole SS, Waghmare VN, Shaikh AM. Clinical Profile and Treatment Outcome of Drug Resistant Tuberculosis Patients of Western Maharashtra, India. J the association of Physicians of India. 2017;65:18-21.

Janmeja AK, Aggarwal D, Dhillon R. Analysis of treatment outcome in multi-drug resistant tuberculosis patients treated under programmatic conditions. Int J Res Med Sci. 2017Jun;5(6):2401-5.

Törün T, Güngör G, Ozmen I, Bölükbaşi Y, Maden E, Biçakçi B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Dec;9(12):1373-7.

Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis. 2010; 14:275-81.

Hoa NB, Nhung NV, Khanh PH, Hai NV, Quyen BT. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham NgocThach hospital, Ho Chi Minh City, Vietnam. BMC Res Notes. 2015;8:809.

Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty 2017 Dec 1;6(1):7.

Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009 Sep 9;4(9):e6914.

Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009; 9:153-61.